Mechanical Ventilation Articles & Analysis
45 news found
Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by progressive scarring of the lungs, which severely impairs lung function over time. Developing effective treatments for IPF has been a challenge for the medical community, as the mechanisms driving this disease are complex and not fully understood. To accelerate drug discovery, animal models that closely mimic the ...
In addition to air testing utilizing highly sensitive real-time Polymerase Chain Reaction (PCR) techniques to help to stop the spread of Mycobacterium tuberculosis, CTSI also helps to mitigate exposure risks through their expertise in mechanical ventilation, engineering controls, and other methods to protect patients, workers, and building occupants in healthcare ...
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). ...
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action, has broad applications as an agnostic respiratory stimulant. ...
” Results from the analytical and clinical studies conclude that the Symphony IL-6 Test is an innovative technology for use in Emergency Department and Intensive Care Unit settings to identify COVID-19 patients at higher risk for severe disease, including the requirement for Invasive Mechanical Ventilation (IMV). This conclusion is based on the study ...
N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. N8 Medical is encouraged by preliminary study data and believes that the CeraShield™ ETT will ...
"This funding supports further development of ENA001, which we believe has the potential to improve the standard of care in treating drug-induced respiratory depression with its unique mechanism of action as an agnostic respiratory stimulant." "The drug overdose epidemic in the United States continues to escalate and is growing in complexity with an ever-greater percentage of ...
Important Study Results Included: Determination of increased ventilatory response (minute ventilation) with dosing of ENA001 under hypoxic and hypercapnic conditions in conjunction with low and high doses of propofol. ...
Zimmetry’s building science professionals can help to mitigate exposure concerns with their expertise in mechanical ventilation, engineering controls and other methods to protect building occupants in Puerto Rico and throughout the Caribbean. ...
HUMIDICARE® is a novel Heat and Moisture Exchanger (HME) which visually alerts clinical staff to a dual humidification error in mechanical ventilation circuits. Artificial humidification systems are used with ventilated patients in the operating theatre or intensive care unit. ...
ByMedovate
Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPace™ System, a next generation product, into the RESCUE 3 pivotal clinical study studying faster ventilator independence. Lungpacer is dedicated to natural breathing by developing minimally invasive technologies designed to help patients wean off ...
About ENA-001 Enalare's lead compound, ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathway in the carotid bodies. The compound utilizes the body's own ventilation control system to ...
Chan continued, “ECMO is a machine that pumps and oxygenates blood outside the body when a patient’s lungs are so diseased that mechanical ventilation fails. Without ECMO, these patients – often considered among the sickest in the ICU – would normally die. ...
About ENA-001 Enalare's lead compound, ENA-001, is a one-of-a-kind new chemical entity designed as an agnostic respiratory stimulant. The compound has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body. The compound utilizes the body's own ventilation control system to beneficially ...
About ENA-001 Enalare's lead product, ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The product has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathway in the carotid bodies. The product utilizes the body's own ventilation control system to ...
“The Hemolung will be an important new treatment modality for acute respiratory failure to avoid or mitigate the harms from invasive mechanical ventilation. FDA clearance of the Hemolung is a game-changer for the treatment of these critically ill patients and will usher in a new era of extracorporeal lung support,” said Steven Conrad, MD, PhD, MCCM, ...
About ENA-001 Enalare's lead product ENA-001 is a one-of-a-kind new chemical entity designed as an agnostic respiratory stimulant. The product has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body. The product utilizes the body's own ventilation control system to beneficially ...
For patients who do meet the criteria, diaphragm pacemakers have been found to be a better alternative to mechanical ventilators. They offer greater mobility and independence; the ability to more easily perform daily activities like getting dressed, bathing and transferring from a wheelchair; lower risk of infections, pneumonia, collapsed lungs, airway injuries ...
Sitting easily in line and without the need to break the circuit7, Aerogen is suitable for multiple areas across the hospital including those providing mechanical ventilation, non-invasive ventilation, high flow nasal cannula oxygen therapy as well as use in spontaneously breathing patients on wards, emergency departments and outpatients2. ...
ByAerogen
The trial did not meet statistical significance on the primary endpoint, defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO) or death by Day 28. ...